Reaction Phenotyping of Low-Turnover Compounds in Long-Term Hepatocyte Cultures Through Persistent Selective Inhibition of Cytochromes P450
| Autor: | Sheri Smith, Donald J. Tweedie, Karsten Menzel, Bennett Ma, Michael J. Lyman |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
CYP2D6
Furafylline CYP3A Pharmaceutical Science chemistry.chemical_compound Cytochrome P-450 Enzyme System medicine Cytochrome P-450 Enzyme Inhibitors Humans Drug Interactions CYP2C9 Cells Cultured Pharmacology biology Chemistry CYP1A2 Cytochrome P450 Coculture Techniques Isoenzymes Phenotype Drug development Biochemistry Pharmaceutical Preparations Tienilic acid biology.protein Hepatocytes Microsomes Liver Algorithms medicine.drug |
| Zdroj: | Drug metabolism and disposition: the biological fate of chemicals. 49(11) |
| ISSN: | 1521-009X |
| Popis: | Recognizing the challenges of determining the relative contribution of different drug metabolizing enzymes to the metabolism of slowly metabolized compounds, a cytochrome P450 reaction phenotyping (CRP) method using cocultured human hepatocytes (HEPATOPAC) has been established. In this study, the emphasis on the relative contribution of different cytochrome P450 (P450) isoforms was assessed by persistently inhibiting P450 isoforms over 7 days with human HEPATOPAC. P450 isoform-selective inhibition was achieved with the chemical inhibitors furafylline (CYP1A2), tienilic acid (CYP2C9), (+)-N-3-benzylnirvanol (CYP2C19), paroxetine (CYP2D6), azamulin (CYP3A), and a combination of 1-aminobenzotriazole and tienilic acid (broad spectrum inhibition of P450s). We executed this CRP method using HEPATOPAC by optimizing for the choice of P450 inhibitors, their selectivity, and the temporal effect of inhibitor concentrations on maintaining selectivity of inhibition. In general, the established CRP method using potent and selective chemical inhibitors allows to measure the relative contribution of P450s and to calculate the fraction of metabolism (fm) of low-turnover compounds. Several low-turnover compounds were used to validate this CRP method by determining their hepatic intrinsic clearance and fm, with comparison with literature values. We established the foundation of a robust CRP for low-turnover compound test system which can be expanded to include inhibition of other drug metabolizing enzymes. This generic CRP assay, using human long-term hepatocyte cultures, will be an essential tool in drug development for new chemical entities in the quantitative assessment of the risk as a victim of drug-drug interactions. SIGNIFICANCE STATEMENT An ongoing trend is to develop drug candidates which have limited metabolic clearance. The current studies report a generic approach to conducting reaction phenotyping studies with human HEPATOPAC, focusing on P450 metabolism of low-turnover compounds. Potent and selective chemical inhibitors were used to assess the relative contribution of the major human P450s. Validation was achieved by confirming hepatic intrinsic clearance and fraction of metabolism for previously reported low-turnover compounds. This approach is adaptable for assessment of all drug metabolizing enzymes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|